Short answer
Praxis Precision Medicines, Inc. (PRAX) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 8.01 (Other Events). POWER1 failed its primary endpoint in highly refractory focal onset seizures, undermining vormatrigine’s near-term approval prospects.
Praxis Precision Medicines, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- POWER1 failed its primary endpoint in highly refractory focal onset seizures, undermining vormatrigine’s near-term approval prospects
- Secondary 50% response-rate endpoint met, with stronger seizure reduction during higher-dose 30 mg treatment
- Vormatrigine generally well tolerated, with adverse-event discontinuations below 10%
- Approximately 90% of treated patients transitioned to and remain in the open-label extension
- POWER2 enrollment paused pending program reassessment, creating timeline and development-strategy uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Praxis Precision Medicines, Inc. 8-K filings
Get the next PRAX 8-K as it lands
Follow PRAX for push alerts, or ask the research agent what this filing means.